Polpharma Biologics – The Polish biosimilar powerhouse

Published: 17.08.2020

“Other companies come to us and want CDMO work in the biosimilar space because we know what we’re doing, but our goal is not to become 100% biosimilars. Our goal is to become a leading biologics manufacturer and biosimilars are a part of what we do,” said our Vice President of Strategy, Programs and Portfolio – Alexandra Moulson in an interview with The Center for Biosimilars®.

Read the full interview and find out more about Polpharma Biologics CDMO services, forward expansion and whether COVID-19 had an impact on the company in recent months.
 

Alexandra Moulson
Vice President of Strategy, Programs and Portfolio at Polpharma Biologics

Alexandra Moulson

written by: Polpharma Biologics

Let’s collaborate and create quality biologics together.

Get in touch for more information.

We use cookies

Polpharma Biologics uses cookies and other similar technologies (hereinafter: cookies) on its webpages and mobile applications (hereinafter, jointly, Website). The user can manage cookies independently by changing the web browser settings. If you do not consent for your personal data to be collected via cookies, you should change your web browser settings or stop using the Website.

Using the Website without changing the web browser settings indicates your acceptance of the use of cookies by Polpharma. Acceptance of the web browser settings indicates your consent to profiling on the basis of the information contained in cookies. Consent may be withdrawn at any time. Withdrawal of consent does not affect lawfulness of any processing activities carried out under consent before its withdrawal.

For more details see the Cookie Policy.